Business
Scancell and CRUK to advance cancer immunotherapy
Scancell and CRUK to advance cancer immunotherapy.
About this update from Scancell Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 2811Z Scancell Holdings Plc 14 December 2017 \n\n \n14 December 2017\n \nScancell Holdings Plc\n(\"Scancell\" or the \"Company\")\n \n \nScancell and Cancer Research UK collaborate to advance novel cancer immunotherapy into \nclinical trials\n \nCancer Research UK to progress SCIB2 into a Phase 1/2 study for patients with a range of solid tumours\n \nScancell Holdings PLC, a developer of novel immunotherapies for the treatment of cancer, and Cancer Research UK, the world's leading cancer charity dedicated to saving lives through research, are pleased to announce that they have entered into a Clinical Development Partnership to develop Scancell's ImmunoBody® vaccine, SCIB2, for the treatment of patients with solid tumours, including non-small cell lung cancer (NSCLC). \n \nScancell's ImmunoBody® immunotherapy platform activates the body's immune system by enhancing the uptake and presentation of cancer antigens to help target and eliminate cancer cells. SCIB2, Scancell's second ImmunoBody® therapy, targets an antigen called NY-ESO-1, which is expressed on a range of solid tumours, including NSCLC and oesophageal, ovarian, bladder and prostate cancers, as well as neuroblastoma, melanoma and sarcoma. \n \nUnder the terms of the Clinical Development Partnership, Cancer Research UK will fund and sponsor a UK-based Phase 1/2 clinical trial of SCIB2 in combination with a checkpoint inhibitor in patients with solid tumours, focusing on NSCLC in the first instance. The charity's Centre for Drug Development (CDD) will be responsible for manufacturing the clinical trial supplies of SCIB2, conducting pre-clinical testing, sponsoring and managing the clinical trial, including the clinical trial timelines.\n \nFollowing completion of the Phase 1/2 clinical trial, Scancell will have the option to acquire the rights to the data to support further development of SCIB2 itself. If Scancell elects not to exercise the option, Cancer Research UK will retain the right to take the SCIB2 programme forward in all indications.\n \nProfessor Lindy Durrant, Chief Scientific Officer of Scancell, commented: \"We are delighted to announce this partnership with Cancer Research UK, which is a significant endorsement for our ImmunoBody® technology. The charity's world-renowned expertise wil...